197A.T
TAUNS Laboratories,Inc.
スタンダード · 医薬品 · 医薬品 · JP
JPY 501.00
−0.99%Income statement
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | 14.9B | 18.6B | 18.4B |
| Cost of Revenue | 738.4M | 5.9B | 5.9B |
| Gross Profit | 1.6B | 12.8B | 12.5B |
| Operating Expenses | |||
| R&D Expense | — | — | — |
| SG&A Expense | 1.1B | 4.5B | 4.5B |
| General & Admin Expense | — | — | — |
| Selling & Marketing Expense | — | — | — |
| Other Expenses | — | — | — |
| Total Operating Expenses | 1.1B | 4.5B | 4.5B |
| Cost and Expenses | 9.9B | 10.4B | 10.4B |
| Operating Income (EBIT) | 5.0B | 8.3B | 8.0B |
| Non-Operating | |||
| Interest Income | 8.4M | 4.7M | 37.0K |
| Interest Expense | 50.8M | 102.9M | 31.2M |
| Net Interest Income | (42.3M) | (98.2M) | (31.2M) |
| Other Non-Op Income/Expense | (42.2M) | (45.1M) | (189.5M) |
| Non-Operating Income (excl Interest) | 324.0K | 55.9M | 63.8M |
| EBT (Pre-Tax Income) | 506.2M | 8.2B | 7.8B |
| Income Tax Expense | 148.3M | 1.9B | 2.1B |
| Bottom Line | |||
| Net Income | 3.7B | 6.3B | 5.8B |
| Earnings from Cont. Ops | — | — | — |
| Earnings from Discont. Ops | — | — | — |
| Bottom Line Net Income | 3.7B | 6.3B | 5.8B |
| Per Share | |||
| Basic EPS | ¥36 | ¥62 | ¥58 |
| Diluted EPS | ¥36 | ¥59 | ¥58 |
| Revenue Per Share | ¥144 | ¥183 | ¥184 |
| Shares | |||
| Basic Shares Outstanding | 103.7M | 101.7M | 100.0M |
| Diluted Shares Outstanding | — | — | — |
| Profitability Metrics | |||
| EBITDA | — | 9.0B | 8.7B |
| D&A | — | 715.4M | 676.2M |
| EBIT | 5.0B | 8.3B | 8.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026